Regenicin Total Current Liabilities

Regenicin (RGIN) currently reports a total current liabilities of $0 as of September 2023. That compares with $5.6M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Regenicin's total current liabilities history and peer comparisons.

Regenicin's total current liabilities decreased from $5.6M to $0 — a 100.0% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regenicin reported $0 in total current liabilities as of September 2023. That compares with $5.6M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Regenicin, and consider following RGIN for alerts when major investors trade the stock.

Regenicin is classified in the Industrials sector. On total current liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing RGIN with unrelated industries.